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Protocol
AbstrAct
Introduction Patients with chronic kidney disease (CKD) 
display increased infection-related mortality and elevated 
cardiovascular risk only partly attributed to traditional risk 
factors. Patients with CKD also exhibit a pro-inflammatory 
environment and impaired immune function. Aerobic 
exercise has the potential to positively impact these 
detriments, but is under-researched in this patient 
population. This feasibility study will investigate the effects 
of acute aerobic exercise on inflammation and immune 
function in patients with CKD to inform the design of larger 
studies intended to ultimately influence current exercise 
recommendations.
Methods and analysis Patients with CKD, including 
renal transplant recipients, will visit the laboratory on two 
occasions, both preceded by appropriate exercise, alcohol 
and caffeine restrictions. On visit 1, baseline assessments 
will be completed, comprising anthropometrics, body 
composition, cardiovascular function and fatigue and 
leisure time exercise questionnaires. Participants will then 
undertake an incremental shuttle walk test to estimate 
predicted peak O
2 consumption (VO2peak). On visit 2, 
participants will complete a 20 min shuttle walk at a 
constant speed to achieve 85% estimated VO2peak. Blood 
and saliva samples will be taken before, immediately after 
and 1 hour after this exercise bout. Muscle O2 saturation 
will be monitored throughout exercise and recovery. Age 
and sex-matched non-CKD ‘healthy control’ participants 
will complete an identical protocol. Blood and saliva 
samples will be analysed for markers of inflammation and 
immune function, using cytometric bead array and flow 
cytometry techniques. Appropriate statistical tests will be 
used to analyse the data.
Ethics and dissemination A favourable opinion was 
granted by the East Midlands-Derby Research Ethics 
Committee on 18 September 2015 (ref 15/EM/0391), 
and the study was approved and sponsored by University 
Hospitals of Leicester Research and Innovation (ref 11444). 
The study was registered with ISRCTN (ref 38935454). 
The results will be presented at relevant conferences, 
and it is anticipated that the reports will be published in 
appropriate journals in 2018.
InTroducTIon
Patients with all stages of chronic kidney 
disease (CKD) have elevated cardiovascular 
disease (CVD) risk that cannot be fully 
explained by traditional risk factors.1 CVD 
is the most common cause of death among 
patients with CKD (23% in 2013), followed by 
infection (19% in 2013).2
Patients with CKD are often sarcopenic 
and obese,3–6 and further deterioration 
in these characteristics is often observed 
after renal transplantation.7–9 Patients 
with CKD and renal transplant recipients 
(RTRs) also frequently suffer from chronic 
systemic inflammation,10 11 which can worsen 
cachexia and increase cardiovascular risk 
in CKD.12 13 Patients with CKD and RTRs 
also display impaired cellular immune func-
tion,14–16 which may explain why infection 
is the second-leading cause of death in 
this population.2 This effect (ie, impaired 
immune function) is further compounded in 
RTRs by the immunosuppressive drug regime. 
Impaired immune function may further 
exacerbate inflammation due to alterations 
in circulating immune cell subsets17 which 
could serve to worsen body composition and 
increase cardiovascular risk. Finally, patients 
with CKD display elevated levels of circulating 
prothrombotic microparticles (MPs),18 which 
may worsen CVD risk and/or burden.19
Exercise has the potential to benefit 
and improve many of the aforementioned 
inter-related morbidities. In the general 
population, exercise can positively impact 
on weight gain,20 muscle wasting,21 phys-
ical capacity22 and fatigue.23 Furthermore, 
moderate aerobic exercise can also modify 
systemic inflammation,24 25 bolster immune 
Strengths and limitations of this study
 ► Inclusion of control group matched for age and sex.
 ► A variety of outcome measures to inform future 
study design.
 ► Pragmatic study design which will inform future 
exercise recommendations for patients with CKD.
 ► No non-exercise control visit.
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function via alterations in circulating immune cell popu-
lations and activity and reduce circulating MP levels.26–29
In the CKD population, similar positive effects of 
exercise on body composition, physical function and 
quality of life have been demonstrated30–33; however, the 
research on inflammation and immune function in this 
population is limited. Previous research has shown that 
30 min of moderate intensity walking exercise elicited a 
normal pattern of leucocyte and monocyte activation, 
while enhancing granulocyte function and promoting an 
anti-inflammatory environment (increased IL-10 release) 
in patients with pre-dialysis CKD.34 However, in a similar 
population, an exhaustive bout of cycling exercise elic-
ited a shift towards the more proinflammatory CD16+ 
monocyte, potentially favouring inflammation.35 This 
disparity may be due to the exercise intensities investi-
gated—moderate intensity exercise is more beneficial in 
strengthening immune function and preventing infec-
tion26 and is promoted in general exercise guidelines. As 
such, investigating the effects of moderate intensity exer-
cise in this patient population is more pragmatic and will 
help to guide future exercise recommendations, which 
are lacking in this patient population.
Therefore, this feasibility study aims to investigate the 
effects of acute aerobic walking exercise on the inflam-
mation and immune function in patients with CKD. 
This will create the basis from which a larger trial can be 
conducted, including data for a power calculation, which 
will ultimately help to inform exercise recommendations 
in this population which are currently lacking, particularly 
with regards to immune function and inflammation.36 
However, a preliminary power calculation (GPower 
V.3.1) based on the findings of Viana et al34 concerning 
total lymphocyte count (based on a statistical power of 
0.80 and an alpha level of 0.05) suggests that 15 partici-
pants per group (eg, predialysis CKD, RTRs and healthy 
controls) will be sufficient.
MeThods and analysIs
outcomes to be measured
This study will investigate the effect of 20 min of moderate 
intensity walking exercise on immune cell subsets and 
inflammatory markers. Participants will be grouped based 
on their status (ie, ‘patient’ or ‘healthy control’). Both 
groups will complete an identical acute, cross-sectional 
study protocol necessitating two study visits, as explained 
below.
Participant recruitment
All patients with CKD attending outpatient clinics within 
the University Hospitals of Leicester renal network will 
be screened for eligibility by their consultant nephrolo-
gist prior to recruitment, and approached during their 
routine outpatient appointments. The inclusion and 
exclusion criteria for patients are summarised in table 1. 
Healthy age-matched and sex-matched controls with 
no known chronic disease will be recruited from the 
local community. Those who do not believe themselves 
to suffer from any significant chronic disease will be 
eligible to participate. The ‘broad’ inclusion and exclu-
sion criteria allow the incorporation of several different 
groups (ie, patients with non-dialysis CKD, with dialysis, 
RTRs and healthy controls), and thus will allow compar-
ison between these groups. Similarly, the wide range of 
CKD stage will allow the influence of remaining renal 
function on the measured markers to be investigated.
Trial design and timeline
This is a non-randomised, controlled, feasibility study. 
Participants will complete two study visits as described 
below.
Visit 1
Participants will arrive at the laboratory in the morning, 
unfasted but having consumed no caffeine or alcohol 
and completed no strenuous exercise for 24 hours. 
Participants will complete questionnaires about time 
spent in leisure activity and their perception of fatigue, 
and assessments of anthropometry, body composition 
and cardiovascular condition. Participants will then 
undertake the Incremental Shuttle Walk Test (ISWT), 
followed by the Endurance Shuttle Walk Test (ESWT) 
as explained below. If the participant cannot complete 
the full 20 min duration of the ESWT, they will be with-
drawn from the study.
Visit 2
Participants will arrive at the laboratory in the morning 
(8–10 am, to minimise the influence of diurnal variation 
Table 1 Inclusion and exclusion criteria for patients
Inclusion criteria Exclusion criteria
 ► Established chronic kidney 
disease (all stages will be 
eligible including those 
with an established kidney 
transplant and those 
receiving dialysis treatment)
 ► Age under 18 years
 ► Pregnancy
 ► Received kidney transplant less than 6 months prior to study entry
 ► Any element of study assessment protocol considered by principle care provider to be 
contraindicated due to physical impairment, comorbidity or any other reason
 ► Inability to give informed consent for any reason
 ► Visual or hearing impairment or insufficient command of English to give informed consent 
or comply with the assessment protocol
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on immune parameters), following the same standard-
isation procedure as in visit 1. After resting for 10 min, 
blood and saliva samples will be collected. The ESWT 
will then be completed at the same speed as in visit 1, 
lasting for 20 min. Within 5 min of exercise cessation, 
another blood and saliva sample will be collected. 
The participant will then rest for 1 hour, after which 
a final blood and saliva samples will be collected. This 
protocol is summarised in a schematic in figure 1, and 
the outcome measures are explained in greater detail 
below.
 The time delay between recruitment, visit 1and visit 
2 will be kept to a minimum to prevent deconditioning 
and minimise dropout rates. For dialysis patients, 
both study visits will be completed on a non-dialysis 
day that is not after their ‘long break’ (ie, weekend 
or two consecutive days without dialysis based on their 
regular shift pattern) to minimise the effect of fluid 
overload.
Physical performance
Endurance capacity will be assessed using the ISWT37 
and ESWT.38 In the ISWT, the participant walks a level 
10 m shuttle course at a speed controlled by an external 
audible bleep signal. The test progressively increases at 
1 min interval for a total of 12 intervals and is termi-
nated when the participant fails to complete a shuttle 
within the required time. Following the ISWT, a walking 
speed equating to 85% of predicted peak O2 consump-
tion (VO2 peak) can be calculated, using a conversion 
table based on their ISWT performance. The ESWT 
is completed at this continuous speed on the same 
shuttle course until volitional exhaustion or the end 
of the test (20 min) is reached. For the purposes of 
this study, any participant who does not complete the 
full 20 min of the ESWT in visit one will be excluded 
to ensure standardisation of the test in visit 2. This 
protocol was initially developed for use in patients with 
chronic airways obstruction37 but has been used in the 
CKD population,39 40 showing good reproducibility and 
a high correlation with VO2peak.
41
Venous blood sampling
Venous blood will be collected using venepuncture of the 
antecubital vein of either arm—provided the absence of 
an arteriovenous fistula. Blood will be drawn through a 
21- gauge needle (30 mL per time point) and collected 
into di-potassium EDTA, sodium citrate, sodium heparin 
and blank monovettes.
Blood processing, storage and analysis
Blood collected into EDTA tubes will be centrifuged 
at 4°C; the supernatant will then be aliquoted and 
frozen at −80°C for future analysis. A cytometric bead 
array technique will be used to allow bulk analysis of 
a panel of proinflammatory and anti-inflammatory 
cytokines, including but not limited to IL-1, IL-2, 
IL-6, IL-10, tumour necrosis factor alpha and inter-
feron gamma. Blood collected into sodium citrate42 will 
be double centrifuged at room temperature (15 min at 
2500 g, supernatant aliquoted followed by another 15 
min at 2500 g) to create platelet-poor plasma; the super-
natant will then be aliquoted and frozen at −80°C for 
future phenotyping of microparticles using flow cytom-
etry, as explained below. Blood collected into sodium 
heparin will be analysed on the day of collection for 
immune cell subsets using flow cytometry, as explained 
below. Blood collected into blank monovettes will be 
sent to the Diagnostic Pathology Service at University 
Hospitals of Leicester National Health Service (NHS) 
Trust on the day of collection for renal profile analysis, 
which includes estimated glomerular filtration rate, 
urea, bicarbonate, creatine, sodium, potassium and 
phosphate measures. This will be completed for both 
patient and control populations.
Flow cytometry
Immune cells will be characterised based on their 
expression of surface antigens using flow cytom-
etry. Monocyte subsets will be categorised as classical 
(CD14++CD16-), intermediate (CD14++CD16+) and 
non-classical (CD14+CD16++).43 Monocyte angioten-
sin-converting enzyme expression will be assessed using 
CD143, with immunoglobulin G1 as a negative control. 
T cells will be categorised as helper (CD3+CD4+) cyto-
toxic (CD3+CD8+) and regulatory (CD4+CD25+CD127-) 
T cells. B Cells will be identified as CD3+CD19+ and NK 
Cells as CD3-CD56+. Following appropriate staining and 
washing procedures, immune cells will be analysed on 
an FACSCalibur (BD Biosciences, Oxford, UK). Acquisi-
tion templates and preliminary flow cytometry results are 
displayed in figure 2.
Microparticles will be characterised based on their size, 
Annexin-v expression, cellular derivation and prothrom-
botic potential. Cellular derivations will be categorised as 
platelet derived (CD42b+), neutrophil derived (CD66b+), 
monocyte derived (CD14+) and endothelial cell derived 
(CD144+). Prothrombotic potential will be estimated 
using Tissue Factor (CD142+) expression. Following the 
thawing of platelet-free plasma at room temperature, 
samples will be double centrifuged at room temperature 
(30 min at 18 000 g, supernatant removed, discarded and 
replaced with an equal volume of buffer, followed by 
another 30 min at 18 000 g). Samples will then undergo 
appropriate staining procedures with the antibodies listed 
above, after which microparticles will be analysed on a 
BD Accuri C6 (BD Biosciences, Oxford, UK) flow cytom-
eter. Acquisition templates and preliminary microparticle 
Figure 1 Visit 2 exercise and sample collection protocol. 
↓, venous blood and saliva collection. ESWT, Endurance 
Shuttle Walk Test.
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results are displayed in figure 3. The protocol for isolating 
and analysing MPs is based on a number of publica-
tions42 44 45 and in our experience produces reliable 
results (figure 3).
saliva sampling and storage
Saliva samples will be collected into sterile plastic 
containers. Participants will swallow to empty the mouth, 
then open and hold the container themselves before 
performing a passive dribble of saliva collected under 
the tongue over the next 2 min. Following centrifugation, 
the supernatant will be aliquoted and frozen for future 
analysis, primarily for secretory IgA to investigate mucosal 
immunity.
anthropometric measures
Height, weight and waist and hip circumference will be 
measured using standard procedures.46
Body composition
Body composition parameters (ie, fat and fat-free mass 
content) will be measured using bioelectrical impedance 
analysis (BIA) (Inbody 370, Chicago, Illinois, USA). BIA 
has been validated for use in CKD.47 While BIA has limita-
tions with regards to reliability and is not recommended 
for tracking changes in body composition, body compo-
sition will only be used as a descriptive rather than an 
outcome variable, and thus BIA has been deemed suit-
able to assess body composition for this reason.
cardiovascular condition and function
Cardiac bioreactance analysis will be carried out using a 
Non-Invasive Cardiac Output Monitor (Cheetah Medical, 
Maidenhead, UK). Cardiac bioreactance is a quick, safe, 
validated48 and non-invasive method of assessing central 
haemodynamics including heart rate, stroke volume, 
cardiac output and total peripheral resistance. This is 
accomplished by using cutaneous electrodes placed on 
the chest in combination with an automatic sphygmoma-
nometer to measure blood pressure.
Time spent in leisure activities
The Leisure Time Exercise Questionnaire assesses the 
amount of exercise a patient undertakes, from which a 
metabolic equivalent estimation can be calculated. It also 
identifies preferred physical activities.
Figure 2 Demonstration of the gating strategy used to 
identify immune cell subsets. (A) Total monocyte gating. 
(B) Monocyte subsets (R3 = classical (CD14++CD16-), 
R4 = intermediate (CD14++CD16+), R5 = non-classical 
(CD14+CD16++) (R1 and R2 were used as preliminary 
gating to remove neutrophils). (C) Total lymphocyte gating. 
(D) Gating CD8+ cytotoxic T lymphocytes in the upper right 
quadrant. (E) Gating CD4+ helper T lymphocytes in the upper 
right quadrant. (F) Gating B lymphocytes (CD3-CD19+) in 
the upper left quadrant. (G) Initial T-Reg gating, identifying 
CD4+ lymphocytes. (H) Secondary T-reg gating, back-gated 
onto plot G, further identifying the CD4+ lymphocytes that 
are CD25+CD127-. Not all graphs display 100% of acquired 
cells—this has been altered independently to allow ease of 
gating. 
Figure 3 Demonstration of the gating strategy used to 
characterise microparticles. (A) ‘All microparticles’ set 
using beads of known size. (B) ‘All microparticles’ based on 
Annexin-v expression. (C) Phenotype marker expression, 
used to quantify microparticles of different cellular sources. 
(D) Prothrombotic potential, assessed by Tissue Factor 
expression. All gates have been appropriately sized and 
positioned using unstained samples to distinguish negative 
versus positive staining. FITC, fluorescein isothiocyanate; F/
SSC-H, Forward/Side Scatter-Height; PE phycoerythrin. 
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Fatigue
Fatigue is a common complaint CKD, and it has 
multiple potential mechanisms including anaemia49 and 
cachexia.50 To assess self-reported fatigue, participants will 
be asked to fill in a fatigue scale (an internally designed 
Likert scale see online supplementary material), as well 
as the validated Functional Assessment of Chronic Illness 
Therapy-Fatigue51 which has been extensively used in 
CKD populations52
Muscle o2 saturation
Reduced muscle O2 saturation is another possible phys-
iological mechanism of fatigue53 and may be related to 
increased inflammation.54 A small non-invasive muscle 
O2 saturation device (BSXInsight, BSXAthletics, Texas, 
USA) will be fitted around the participant’s calf and worn 
during exercise bouts and subsequent recovery. This 
device uses near infrared spectroscopy (NIRS) to measure 
haemoglobin and myoglobin oxygenation (muscle O2 
tissue stores). NIRS has previously been used in a variety 
of disease conditions.55
clinical information
Clinical records will be used to extract information that 
allows associations to be made with physical activity levels 
and account for confounding variables, including: age, 
gender, ethnicity, primary cause of renal failure, trans-
plant or dialysis type, time since transplant or duration of 
dialysis, comorbidities and current medications.
data analysis plan
Mixed-design analyses of variance will be used to analyse 
main effects of group and time and interaction effects, 
with Bonferroni post hoc testing used to elucidate these 
effects. This will generate both tests of significance and 
estimates of effect sizes. Any non-normally distributed 
data will first be transformed appropriately to ensure 
normality assumptions are met, to increase statistical 
power and to allow clear conclusions to be drawn from 
the data. Where normality assumptions cannot be met via 
data transformation, Friedman’s tests will be employed as 
a non-parametric alternative. This will allow the genera-
tion of hypotheses for future, larger studies.
ethics and dissemination
Ethical and safety considerations
This protocol was reviewed by the East Midlands-
Derby Research Ethics Committee (REC) and was 
given a favourable opinion (REC ref 15/EM/0391) on 
24 September 2015. Additionally, local approval was given 
by the Research and Innovation office at the Univer-
sity Hospitals of Leicester NHS Trust (ref 11444) on 
29 September 2015. Therefore, all steps have been taken 
when designing this protocol to minimise all ethical 
implications and ensure patient welfare. Two substan-
tial amendments were made to this protocol, approved 
on 03 December 2015 and 01 August 2016 to add saliva 
collection and fatigue questionnaires and muscle O2 
saturation, respectively. The protocol presented here 
represents the most up-to-date version.
dissemination plan
The results are planned for publication in early 2018. We 
plan to present the data at relevant national and inter-
national conferences, as well as publish the findings in 
relevant journals. Participant level data will be available 
at a later date.
Trial registration
This study is registered with the ISRCTN 
(ISRCTN38935454). The registration was completed 
after recruitment of the first patient, so the study was 
registered retrospectively.
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